Eszter Szalai1,2, Yi Jiang3, Natasha M van Poppelen4,5, Martine J Jager6, Annelies de Klein5, Emine Kilic4, Hans E Grossniklaus1,7. 1. Department of Ophthalmology, Emory University School of Medicine, Atlanta, Georgia. 2. Department of Ophthalmology, University of Debrecen, Debrecen, Hungary. 3. Department of Mathematics and Statistics, Georgia State University, Atlanta. 4. Department of Ophthalmology, Erasmus University Medical Center, Rotterdam, the Netherlands. 5. Department of Clinical Genetics, Erasmus University Medical Center, Rotterdam, the Netherlands. 6. Department of Ophthalmology, Leiden University Medical Centre, Leiden, the Netherlands. 7. Department of Pathology, Emory University School of Medicine, Atlanta, Georgia.
Abstract
Importance: It is necessary to understand the mechanisms of metastasis of uveal melanoma to advise patients and develop treatments for this tumor. Objective: To examine the stochastic properties of primary uveal melanoma including the mutation rate as a function of tumor size and metastatic rate relative to the type of mutation. Design, Setting, and Participants: We computed the mutation rate in different sized uveal melanomas using previously published large data sets. Tumor volume was estimated using the spherical cap method. We also calculated the metastatic rate using an updated data set of patients with uveal melanoma with known mutations in BAP1, SF3B1, and EIF1AX provided by the Rotterdam Ocular Melanoma Study Group. Data were analyzed from 2 studies, one taking place from August 25, 1970, to August 27, 2008, and the other taking place between 1993 and 2013. Data were analyzed between 2016 and 2017. Main Outcomes and Measures: Mutation rates and metastic rates. Results: Based on the 5-year metastatic rates, mutation rates ranged from 1.09 × 10-8 to 7.86 × 10-7 per cell division, using our calculation algorithm. A higher mutation rate was found for tumors with smaller thicknesses. EIF1AX mutations were not exclusive of other mutations because 2 cases with EIF1AX mutations and metastasis also had BAP1 mutations. None of the tumors with only an EIF1AX mutation metastasized. After plotting the yearly metastatic rate vs time after treatment, we observed a small peak at 1 year and a large peak at 3.5 years after treatment for BAP1 mutations, with peaks between 2 and 3 years and at 7 years for SF3B1 mutations. Conclusions and Relevance: We observed a higher mutation rate for smaller tumors, which may be explained by a greater number of cell divisions occurring during the expansion phase of smaller uveal melanomas. Regarding time to clinically detected metastases, the first 2 peaks appear to be associated with BAP1-mutated tumors and the late peak to SF3B1-mutated tumors.
Importance: It is necessary to understand the mechanisms of metastasis of uveal melanoma to advise patients and develop treatments for this tumor. Objective: To examine the stochastic properties of primary uveal melanoma including the mutation rate as a function of tumor size and metastatic rate relative to the type of mutation. Design, Setting, and Participants: We computed the mutation rate in different sized uveal melanomas using previously published large data sets. Tumor volume was estimated using the spherical cap method. We also calculated the metastatic rate using an updated data set of patients with uveal melanoma with known mutations in BAP1, SF3B1, and EIF1AX provided by the Rotterdam Ocular Melanoma Study Group. Data were analyzed from 2 studies, one taking place from August 25, 1970, to August 27, 2008, and the other taking place between 1993 and 2013. Data were analyzed between 2016 and 2017. Main Outcomes and Measures: Mutation rates and metastic rates. Results: Based on the 5-year metastatic rates, mutation rates ranged from 1.09 × 10-8 to 7.86 × 10-7 per cell division, using our calculation algorithm. A higher mutation rate was found for tumors with smaller thicknesses. EIF1AX mutations were not exclusive of other mutations because 2 cases with EIF1AX mutations and metastasis also had BAP1 mutations. None of the tumors with only an EIF1AX mutation metastasized. After plotting the yearly metastatic rate vs time after treatment, we observed a small peak at 1 year and a large peak at 3.5 years after treatment for BAP1 mutations, with peaks between 2 and 3 years and at 7 years for SF3B1 mutations. Conclusions and Relevance: We observed a higher mutation rate for smaller tumors, which may be explained by a greater number of cell divisions occurring during the expansion phase of smaller uveal melanomas. Regarding time to clinically detected metastases, the first 2 peaks appear to be associated with BAP1-mutated tumors and the late peak to SF3B1-mutated tumors.
Authors: Mehmet Dogrusöz; Mette Bagger; Sjoerd G van Duinen; Wilma G Kroes; Claudia A L Ruivenkamp; Stefan Böhringer; Klaus Kaae Andersen; Gregorius P M Luyten; Jens F Kiilgaard; Martine J Jager Journal: Invest Ophthalmol Vis Sci Date: 2017-02-01 Impact factor: 4.799
Authors: Josep M Caminal; Karol Mejía; Luis Arias; Cristina Masuet-Aumatell; Jon Larrucea-Maseda; Ignasi Modolell; Daniel Lorenzo; Jaume Català; Marc Rubio; Estefanía Cobos; Pere Garcia-Bru; Ignacio Flores; Alejandro Filloy; Jordi Arruga Journal: Am J Ophthalmol Date: 2016-04-08 Impact factor: 5.258
Authors: Christina L Decatur; Erin Ong; Nisha Garg; Hima Anbunathan; Anne M Bowcock; Matthew G Field; J William Harbour Journal: JAMA Ophthalmol Date: 2016-07-01 Impact factor: 7.389
Authors: Scott D Walter; Daniel L Chao; William Feuer; Joyce Schiffman; Devron H Char; J William Harbour Journal: JAMA Ophthalmol Date: 2016-07-01 Impact factor: 7.389
Authors: M J C Vader; M C Madigan; M Versluis; H M Suleiman; G Gezgin; N A Gruis; J J Out-Luiting; W Bergman; R M Verdijk; M J Jager; P A van der Velden Journal: Br J Cancer Date: 2017-08-15 Impact factor: 7.640
Authors: Elgilda Musi; Gary K Schwartz; Jae Hyuk Yoo; Shannon J Odelberg; Dean Y Li; Michael Y Bonner; Ponniah Selvakumar; Shikha Rao; Linda C Gilbert; Justin Elsey; Jack L Arbiser Journal: Oncotarget Date: 2019-07-08
Authors: Tomasz M Grzywa; Agnieszka A Koppolu; Wiktor Paskal; Klaudia Klicka; Małgorzata Rydzanicz; Jarosław Wejman; Rafał Płoski; Paweł K Włodarski Journal: Int J Mol Sci Date: 2021-04-09 Impact factor: 5.923
Authors: Mizue Terai; Ayako Shimada; Inna Chervoneva; Liam Hulse; Meggie Danielson; Jeff Swensen; Marlana Orloff; Philip B Wedegaertner; Jeffrey L Benovic; Andrew E Aplin; Takami Sato Journal: Cancers (Basel) Date: 2021-11-17 Impact factor: 6.639
Authors: Wojtek Drabarek; Job van Riet; Josephine Q N Nguyen; Kyra N Smit; Natasha M van Poppelen; Rick Jansen; Eva Medico-Salsench; Jolanda Vaarwater; Frank J Magielsen; Tom Brands; Bert Eussen; Thierry P P van den Bosch; Robert M Verdijk; Nicole C Naus; Dion Paridaens; Annelies de Klein; Erwin Brosens; Harmen J G van de Werken; Emine Kilic Journal: Cancers (Basel) Date: 2022-02-08 Impact factor: 6.639
Authors: Elias A T Koch; Anne Petzold; Anja Wessely; Edgar Dippel; Michael Erdmann; Lucie Heinzerling; Bettina Hohberger; Harald Knorr; Ulrike Leiter; Friedegund Meier; Peter Mohr; Farnaz Rahimi; Beatrice Schell; Max Schlaak; Patrick Terheyden; Beatrice Schuler-Thurner; Selma Ugurel; Jochen Utikal; Julio Vera; Michael Weichenthal; Fabian Ziller; Carola Berking; Markus V Heppt Journal: Cancer Immunol Immunother Date: 2021-10-28 Impact factor: 6.630